Note 9 - Business Segment Reporting

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

9.          Business Segment Reporting

The Company manages its operations as one segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. All Brazil sales are through one independent distributor. The Company’s revenues by geographic region are as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
Consolidated Revenue:
United States	$	6,338	$	4,977	$	17,340	$	14,441
Brazil		180		62		639		1,207
Other		155		135		494		377
Total Revenue	$	6,673	$	5,174	$	18,473	$	16,025